Skip to content
Agentic OS
Menu

Intelligence / Healthtech / De Novo Grants / Abbott Diabetes Care

Approvalsnovel device granted (FDA De Novo)25 Aug 2026

Abbott Diabetes Care

25 Aug 2026: Novel device granted (FDA De Novo) · Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System. Recorded in the openFDA device 510(k) (De Novo decisions).

View the source record

Granted
25 Aug 2026
Device
Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System
Specialty
Clinical Chemistry
Product Code
SJD
Country
United States
Location
Alameda, CA
Submitted
2025-09-29
Reference
DEN250049
What this signal means

A De Novo grant creates a new device category: reimbursement coding, distribution, clinical evidence, manufacturing scale-up and sales hires follow.

  1. 2 added in the 30 days to 19 Nov 2026.
  2. Neurology leads (10); 29% went to makers outside the US.
Reach them with AOS

Find the decision makers at Abbott Diabetes Care

AOS maps the buying committee, finds verified work emails and drafts outreach that cites this approvals signal, for your approval.

Start free

Across AOS Research

Other records for Abbott Diabetes Care in our registers.

More in Clinical Chemistry

De Novo Grants

See all

Source: openFDA device 510(k) (De Novo decisions), data to 19 Nov 2026. Every De Novo classification FDA granted in the last 24 months: a novel device with no legally marketed predicate, which creates a new device type and product code. AOS shows what the public record says; it does not verify or endorse the company.